ZENEO® Naloxone : Treatment in opioid overdose
ZENEO® Naloxone is a veritable emergency antidote for overdoses due to opiates (e.g., synthetic derivatives of opium and synthetic psychotropic drugs).
According to United Nations data, opiate use is present in 2% of the American population and is growing by 10% each year.
The proportion of opiate users is lower in Europe at 0.67%.
Worldwide, 5.1 million people use opiates.
Returning to the U.S., the weight of opioid analgesics in overdose deaths is striking (1).
In 2015, according to the Centers for Disease Control and Prevention, there were 15,000 deaths due to opioid painkiller overdoses. That number represents nearly half of all opiate overdose deaths (33,091) and nearly a third of drug overdose deaths (50,000).
Worldwide, opiate abuse causes 100,000 deaths by overdose every year, making it the leading cause of accidental death (2).
Opiate overdoses kill by suppressing the central nervous and respiratory systems.
Naloxone is used as an emergency treatment to counter the effects of opiates on those systems and thus increase the patient's chance of survival. In the hands of potential victims, their loved-ones, their assistants, or healthcare providers, ZENEO® Naloxone will contribute greatly to saving lives. Furthermore, its needle-free nature will reduce the risk of accidental transmission of blood-borne infectious diseases such as hepatitis C or HIV.
(1) Le Monde science et techno, 24 April 2017
(2) Datamonitor 2015
When experiencing an opioid overdose, the patient can self-administer ZENEO® Naloxone in the thigh.
Another person could also administer the product for the patient, in a ventrogluteal injection.